A detailed history of Pathstone Family Office, LLC transactions in Navidea Biopharmaceuticals, Inc. stock. As of the latest transaction made, Pathstone Family Office, LLC holds 10,043 shares of NAVB stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,043
Previous 10,043 -0.0%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Oct 23, 2023

SELL
$0.18 - $0.3 $1 - $2
-7 Reduced 0.07%
10,043 $2,000
Q4 2022

Feb 13, 2023

SELL
$0.18 - $0.3 $1 - $2
-7 Reduced 0.07%
10,043 $2,000
Q2 2022

Oct 23, 2023

BUY
$0.63 - $1.1 $4 - $7
7 Added 0.07%
10,050 $7,000
Q1 2020

Jun 11, 2020

BUY
$0.76 - $1.54 $7,638 - $15,477
10,050 New
10,050 $8,000
Q1 2020

May 07, 2020

SELL
$0.76 - $1.54 $7,638 - $15,477
-10,050 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.65 - $1.26 $1,641 - $3,181
2,525 Added 33.55%
10,050 $127,000
Q2 2019

Aug 14, 2019

BUY
$0.62 - $3.6 $4,665 - $27,090
7,525 New
7,525 $5,000

Others Institutions Holding NAVB

About NAVIDEA BIOPHARMACEUTICALS, INC.


  • Ticker NAVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,150,900
  • Description
  • Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...
More about NAVB
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.